Drug intelligence / Profile preview

Oncobax FH

Development stage: Preclinical
Lead developer: EverImmune
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Oncobax FH is an oral live biotherapeutic product (LBP) being developed by EverImmune, a biotechnology company focused on 'oncomicrobiotics.' The therapy consists of a specific strain of commensal bacteria, likely belonging to the genus *Faecalibacterium* (as suggested by the 'FH' designation), which is designed to modulate the gut microbiome. Based on the research of founders Dr. Laurence Zitvogel and Dr. Guido Kroemer, Oncobax FH aims to restore gut eubiosis and prime the host immune system to enhance the efficacy of immune checkpoint inhibitors (ICIs). By stimulating systemic immune responses, particularly T-cell activation, the drug is intended to overcome primary resistance to cancer immunotherapies in patients with solid tumors.

Brand names: Oncobax FH

Beyond the preview

Go deeper on Oncobax FH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncobax FH.

Explore the full profile